oncologists – Oral Cancer News

The Cost of Cancer Drugs

Source: www.cbsnew.comAuthor: Lesley Stahl The following is a script of "The Cost of Cancer Drugs" which aired on October 5, 2014, and was rebroadcast on June 21, 2015. Lesley Stahl is the correspondent. Richard Bonin, producer. Cancer is so pervasive that it touches virtually every family in this country. More than one out of three Americans will be diagnosed with some form of it in their lifetime. And as anyone who's been through it knows, the shock and anxiety of the diagnosis is followed by a second jolt: the high price of cancer drugs. They are so astronomical that a growing number of patients can't afford their co-pay, the percentage of their drug bill they have to pay out-of-pocket. As we first reported in October, this has led to a revolt against the drug companies led by some of the most prominent cancer doctors in the country. Dr. Leonard Saltz: We're in a situation where a cancer diagnosis is one of the leading causes of personal bankruptcy. Dr. Leonard Saltz is chief of gastrointestinal oncology at Memorial Sloan Kettering, one of the nation's premier cancer centers, and he's a leading expert on colon cancer. Lesley Stahl: So, are you saying in effect, that we have to start treating the cost of these drugs almost like a side effect from cancer? Dr. Leonard Saltz: I think that's a fair way of looking at it. We're starting to see the term "financial toxicity" being used in the literature. Individual patients are going into [...]

Oral Cancer Foundation News Team - A2015-06-22T11:00:30-07:00June, 2015|Oral Cancer News|

Oncologists Favor Psychosocial Care, But Give It Short Shrift

Source: Oncology STAT MIAMI (EGMN) - Oncologists endorse the idea of connecting cancer patients to psychosocial care at the conclusion of active treatment. But practice doesn't align with beliefs, perhaps because they are unfamiliar with where to refer their patients for care. Among 57 oncologists who responded to a survey in the southeastern United States, 35, or 61%, considered psychosocial care to be beneficial. A majority thought it was "important" following cancer treatment, reported Laurie Freeman-Gibb at the annual conference of the American Psychosocial Oncology Society (APOS). But the oncologists said they spent just 4.2 minutes, on average, discussing psychosocial care during consultations, according to Ms. Freeman-Gibb, a lecturer in the department of nursing at the University of Windsor in Ontario, and her colleague Andrew Hatchett, Ph.D., of the University of Louisiana at Lafayette's department of kinesiology. And since only about 1 in 6 oncologists responded to the survey - it was sent to 350 practitioners - the findings may present an overly optimistic picture of what happens in real-life practice when a patient leaves active treatment and returns to the community for care. "I think it's sometimes a time constraint," said Ms. Freeman-Gibb. "If you only have 20 minutes to see this person and you open the floodgates to what's really going on, you might never get out the door ... especially if you don't know whom to tell the patient to call." Dr. Hatchett said the impetus for the study was a series of conversations he had with [...]

Charlotte Parker2012-05-02T10:45:02-07:00May, 2012|Oral Cancer News|

Implications of the Oropharyngeal Cancer Epidemic

Source: Journal of Clinical Oncology Chaturvedi et al,1 analyzing specimens back to 1984, validate the long-held hypothesis that infection with human papillomavirus (HPV) has increased oropharyngeal squamous cell carcinoma (OPSCC) incidence in the US. They find the incidence of OPSCC in men—who have higher risks of both HPV-positive and HPV-negative OPSCC than women—similar to that of cervical cancer in women. From 1988 to 2004, incidence of HPV-negative OPSCC decreased in parallel with smoking whereas incidence of HPV-positive OPSCC increased at about 7.5% per year, so the percentage of OPSCC that was HPV-positive went from less than 20% to more than 70%. HPV-positive and HPV-negative OPSCC are etiologically and clinically distinct,2,3 with HPV-positive disease having better outcome.4–6 In the current study,1 the hazard ratio of 0.3 for HPV-positive/HPV-negative in survival analysis essentially balances the difference in prevalence so each form of OPSCC now accounts for a similar number of deaths. Notably, the authors found that outcomes for HPV-positive OPSCC have improved over time, whereas outcomes for HPV-negative OPSCC are as dismal as they were 25 years ago. The authors argue convincingly that vaccination to prevent oral HPV infections should be evaluated and that better treatments for both types of OPSCC should be developed. We are unlikely to get a better picture of the recent history of OPSCC in the United States. This study used all available OPSCC specimens from the three Surveillance, Epidemiology, and End Results (SEER) registries that participate in the Residual Tissue Repositories Program, analyzed them in several ways, [...]

Oral Cancer Foundation News Team - A2011-11-09T15:24:59-07:00November, 2011|Oral Cancer News|

High risk of developing ONJ for cancer patients on bisphosphonates

Source: Dr.Bicuspid.com Research has shown that cancer patients on bisphosphonates are at risk of developing osteonecrosis of the jaw (ONJ) and that those on the intravenous form of the drug are at a higher risk compared with those on the oral drugs. However, a new study that looked at cancer patients on zoledronic acid (ZOL) and chemotherapy combined with the antiangiogenic agent bevacizumab (BEV) who underwent a dental exam before starting treatment found that none of them developed ONJ (JADA, May 2011, Vol. 142:5, pp. 506-513). Researchers from the University of Siena in Italy investigated the incidence of and risk factors for ONJ in patients with metastases to the bone from solid tumors who received ZOL and BEV. Their study included 59 patients (34 with breast cancer and 25 with non-small cell lung cancer [NSCL]) who received 4 mg of ZOL intravenously every four weeks and 15 mg per kg of BEV every three weeks. The median time the participants received ZOL therapy was 18 months, while the median time participants received BEV therapy was 16 months. The researchers took several measures to reduce the study participants' risk of developing ONJ, including the following: Dental caries and periodontal disease were treated before starting study treatment. Mouth rinses with chlorhexidine and local antibiotic agents were administered before baseline oral hygiene. Recommendations were made for maintaining good oral hygiene. Teeth were extracted at least four weeks before starting ZOL and BEV therapy. Invasive dental procedures were avoided during treatment. If invasive dental [...]

Oral Cancer Foundation News Team - A2011-05-24T10:21:55-07:00May, 2011|Oral Cancer News|

Oncologists must discuss all options in advanced cancer: ASCO policy

Source: MedScape.com By: Zosia Chustecka January 28, 2011 — A new policy statement from the American Society of Clinical Oncology (ASCO) aims to improve communication with, and decision making for, patients with advanced cancer (defined as incurable disease). It calls for a change in paradigm for advanced cancer care and a new approach in which all available treatment options are discussed from the very beginning. The statement was published online on January 24 in the Journal of Clinical Oncology. "While improving survival is the oncologist's primary goal, helping individuals live their final days in comfort and dignity is one of the most important responsibilities of our profession," ASCO president George Sledge, MD, said in a statement. "Oncologists must lead the way in discussing the full range of curative and palliative therapies to ensure that patients' choices are honored," he said. New Paradigm of Care This new approach "requires stepping back from the paradigm of applying one line of therapy after the other and focusing primarily on disease-directed interventions," say the authors, comprised of a panel of oncologists and specialists in palliative care. "Instead, we need to move toward developing a treatment plan that is consistent with evidence-based options (including disease-directed and palliative care), and the patients' informed preferences for how we pursue and balance these options throughout the course of illness," they add. Conversations about all of the options that are available must be started earlier, and they must be more thorough, the panel insists. "These conversations should be going on [...]

Oral Cancer Foundation News Team - A2011-01-29T11:01:08-07:00January, 2011|Oral Cancer News|